BriaCell: Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer

 

• BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer.
• The combination treatment showed a favorable safety profile in 12 patients.
• Phase II efficacy portion of the study, under FDA’s fast track designation, now underway with survival data and clinical benefit being compiled.

https://www.biospace.com/article/releases/briacell-announces-successful-completion-of-phase-i-portion-of-clinical-study-in-advanced-breast-cancer-randomized-phase-ii-efficacy-evaluation-progressing/